The Cytomx paradox
Failure of the company’s in-house lead raises questions about the viability of its extensively partnered probody technology.
Biotech’s important data reveals
Key upcoming clinical results approach in the third quarter for lecanemab, high-dose Eylea and Zimura.
GSK goes back to its vaccine bread and butter
But breaking Pfizer and Merck’s duopoly will not be easy.
AACR 2022 – A weekend of updates yields few winners
The dour biotech market sees little to be impressed about in updates from Bicycle, Rubius, C4 and Zentalis, though well-received data gives Affimed a boost.
Daiichi could be rewarded for persisting with Vanflyta
A front-line trial yields a positive result two years after the drug got a US complete response letter.
